Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Q4 Sales Outlook Recedes 15 Percent

NEW YORK, Jan. 3 -  Transgenomic reported that fourth-quarter sales would be as much as 15 percent thinner than earlier predictions as the company struggles to meet higher demand for its products.

 

The firm said it now expects revenues for the quarter ended Dec. 31 to be between $10.3 million and $10.6 million, which is still about 40 percent higher than what it reported during the same period last year. Full-year 2001 revenue in this case would be about $38 million.

 

In a statement released on Wednesday, Collin D'Silva, Transgenomic's CEO, said the company expects to grow by 45 percent to 55 percent in 2002, and reasserted his belief that the company will become profitable by the end of the year.

 

The company blamed its shrunken outlook on capacity constraints. The first phase of a manufacturing upgrade designed to help it meet the rising demand for its synthetic nucleic-acid products is set to end by the end of the current quarter.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.